Overview

S-1 and and Gemcitabine vs Gemcitabine Alone as Adjuvant Chemotherapy for Patients With Resected Pancreatic Cancer

Status:
Unknown status

Trial end date:
2017-12-01

Target enrollment:

Participant gender:

Summary

This study is a randomized, open-label, controlled study that will compare the efficacy of S-1 in combination with gemcitabine to gemcitabine alone as adjuvant treatment for patients with surgically resected pancreatic adenocarcinoma.

Phase:

Phase 2

Details

Lead Sponsor:

Zhejiang University

Treatments:

Gemcitabine